Imperial College London
Alternate

ProfessorElaineHolmes

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Professor of Chemical Biology
 
 
 
//

Contact

 

+44 (0)20 7594 3220elaine.holmes

 
 
//

Location

 

661Sir Alexander Fleming BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Alsaleh:2020:10.1016/j.jceh.2019.06.001,
author = {Alsaleh, M and Leftley, Z and Barbera, TA and Koomson, LK and Zabron, A and Crossey, MME and Reeves, HL and Cramp, M and Ryder, S and Greer, S and Prince, M and Sithithaworn, P and Shariff, M and Khuntikeo, N and Loilome, W and Yongvanit, P and Shen, Y-L and Cox, IJ and Williams, R and Wadsworth, CA and Holmes, E and Nash, K and Taylor-Robinson, SD},
doi = {10.1016/j.jceh.2019.06.001},
journal = {Journal of Clinical and Experimental Hepatology},
pages = {17--29},
title = {Characterisation of the serum metabolic signature of cholangiocarcinoma in a United Kingdom cohort},
url = {http://dx.doi.org/10.1016/j.jceh.2019.06.001},
volume = {10},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundA distinct serum metabonomic pattern has been previously revealed to be associated with various forms of liver disease. Here, we aimed to apply mass spectrometry to obtain serum metabolomic profiles from individuals with cholangiocarcinoma and benign hepatobiliary diseases to gain an insight into pathogenesis and search for potential early-disease biomarkers.MethodsSerum samples were profiled using a hydrophilic interaction liquid chromatography platform, coupled to a mass spectrometer. A total of 47 serum specimens from 8 cholangiocarcinoma cases, 20 healthy controls, 8 benign disease controls (bile duct strictures) and 11 patients with hepatocellular carcinoma (as malignant disease controls) were included. Data analysis was performed using univariate and multivariate statistics.ResultsThe serum metabolome disparities between the metabolite profiles from healthy controls and patients with hepatobiliary disease were predominantly related to changes in lipid and lipid-derived compounds (phospholipids, bile acids and steroids) and amino acid metabolites (phenylalanine). A metabolic pattern indicative of inflammatory response due to cirrhosis and cholestasis was associated with the disease groups. The abundance of phospholipid metabolites was altered in individuals with liver disease, particularly cholangiocarcinoma, but no significant difference was seen between profiles from patients with benign biliary strictures and cholangiocarcinoma.ConclusionThe serum metabolome in cholangiocarcinoma exhibited changes in metabolites related to inflammation, altered energy production and phospholipid metabolism. This study serves to highlight future avenues for biomarker research in large-scale studies.
AU  - Alsaleh,M
AU  - Leftley,Z
AU  - Barbera,TA
AU  - Koomson,LK
AU  - Zabron,A
AU  - Crossey,MME
AU  - Reeves,HL
AU  - Cramp,M
AU  - Ryder,S
AU  - Greer,S
AU  - Prince,M
AU  - Sithithaworn,P
AU  - Shariff,M
AU  - Khuntikeo,N
AU  - Loilome,W
AU  - Yongvanit,P
AU  - Shen,Y-L
AU  - Cox,IJ
AU  - Williams,R
AU  - Wadsworth,CA
AU  - Holmes,E
AU  - Nash,K
AU  - Taylor-Robinson,SD
DO  - 10.1016/j.jceh.2019.06.001
EP  - 29
PY  - 2020///
SN  - 0973-6883
SP  - 17
TI  - Characterisation of the serum metabolic signature of cholangiocarcinoma in a United Kingdom cohort
T2  - Journal of Clinical and Experimental Hepatology
UR  - http://dx.doi.org/10.1016/j.jceh.2019.06.001
UR  - https://www.sciencedirect.com/science/article/pii/S0973688319301550?via%3Dihub
UR  - http://hdl.handle.net/10044/1/72084
VL  - 10
ER  -
Download